Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 21-28

  Leonard, Robert ^a,e   Miles, David ^b   Reichardt, Peter ^c   Twelves, Chris ^d  

^a UK   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c HELIOS Klin Char Camp Buch B

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e SINGLETON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PAIN; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DATA ANALYSIS; DIARRHEA; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; PAIN ASSESSMENT; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS;

EID: 5644237780     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.018     Document Type: Conference Paper

References (46)

1. G.N. Hortobagyi, M.J. Piccart-Gebhart Current management of advanced breast cancer Semin Oncol 23 1996 1 5
2. G.W. Sledge, D. Neuberg, P. Bernardo Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer an intergroup trial (E1193) J Clin Oncol 21 2003 588 592
3. E. Alba, N. Ribelles, I. Sevilla Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer Breast Cancer Res Treat 66 2001 33 39
4. E. Rivera, V. Valero, F.J. Esteva Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer Cancer Chemother Pharmacol 49 2002 299 302
5. M. Venturini, P. Bruzzi, L. Del Mastro Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer J Clin Oncol 14 1996 764 773
6. J. Wojtacki, E. Lewicka-Nowak, K. Lesniewski-Kmak Anthracycline-induced cardiotoxicity clinical course, risk factors, pathogenesis, detection and prevention - review of the literature Med Sci Monit 6 2000 411 420
7. J.M. Nabholtz, H.J. Senn, W.R. Bezwoda Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1999 1413 1424
8. S. Jones, J. Erban, B. Overmoyer Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer [abstract 10] Breast Cancer Res Treat 82 suppl 1 2003 S9
9. J.M. Nabholtz, C. Falkson, D. Campos Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer results of a randomized, multicenter, phase III trial J Clin Oncol 21 2003 968 975
10. J. Jassem, T. Pienkowski, A. Pluzanska Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer final results of a randomized phase III multicenter trial J Clin Oncol 19 2001 1707 1715
11. L. Biganzoli, T. Cufer, P. Bruning Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial J Clin Oncol 20 2002 3114 3121
12. H. Lück, C. Thomssen, M. Untch Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/ paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group [abstract 280] Proc Am Soc Clin Oncol 19 2000 73a
13. J. Carmichael UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol (ET) in the first line treatment of women with metastatic breast cancer (MBC) [abstract 84] Proc Am Soc Clin Oncol 20 2001 22a
14. J. Mackey, A. Paterson, L. Dirix Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) [abstract 137] Proc Am Soc Clin Oncol 21 2002 35a
15. J. Bonneterre, V. Dieras, M. Tubiana-Hulin 6 cycles of epirubicin/docetaxel (ET) versus 6 cycles of 5FU epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment [abstract 163] Proc Am Soc Clin Oncol 20 2001 42a
16. J. O'Shaughnessy, D. Miles, S. Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer phase III trial results J Clin Oncol 20 2002 2812 2823
17. J. Blum, V. Dieras, P. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 2001 1759 1768
18. J. Blum, S. Jones, A. Buzdar Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 1999 485 493
19. P. Reichardt, G. Von Minckwitz, P.C. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233
20. P. Fumoleau, R. Largillier, C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer Eur J Cancer 40 2004 536 542
21. N. Batista, G. Perez-Manga, M. Constenla Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer Br J Cancer 90 2004 1740 1746
22. W.J. Gradishar, L.A. Meza, T. Hill A multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer survival update J Clin Oncol 22 2004 2321 2327
23. K.S. Albain, S. Nag, G. Calderillo-Ruiz Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC) first report of overall survival [abstract 510] Proc Am Soc Clin Oncol 23 2004 5A
24. J. O'Shaughnessy, J. Blum, V. Moiseyenko Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 2001 1247 1254
25. G. Procopio, E. Bajetta, L. Gattinoni Safety and activity of capecitabine in elderly patients (pts) with advanced breast cancer (ABC) [abstract 3050] Proc Am Soc Clin Oncol 22 2003 759a
26. D. Talbot, V. Moiseyenko, S. Van Belle Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 2002 1367 1372
27. K. Maung Capecitabine/bevacizumab compared to capecitabine alone in pretreated metastatic breast cancer results of a phase III study Clin Breast Cancer 3 2003 375 377
28. J. Blum, S.E. Jones, A.U. Buzdar Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC updated results and analysis of dose modification [abstract 693] Eur J Cancer 37 suppl 6 2001 190
29. G. Segalla, C.T. Oliveira, S. Lago Quality of life (QoL) in patients with metastatic breast cancer (MBC) treated with capecitabine (Xeloda) [abstract 446] Eur J Cancer 1 suppl 5 2003 S136
30. C.H. Smorenburg, M. Bontenbal, C. Seynaeve Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane Breast Cancer Res Treat 66 2001 83 87
31. T. Brodowicz, W.J. Kostler, R. Moslinger Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer Breast 9 2000 338 342
32. M.R. Valerio, G. Cicero, M.G. Armata Gemcitabine (G) in pretreated breast cancer (BC) [abstract 1953] Proc Am Soc Clin Oncol 20 2001 51b
33. S.Y. Rha, H. Jeung, Y. Kim Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclitaxel based regimen [abstract 2038] Proc Am Soc Clin Oncol 21 2002 57b
34. D.I. Udom, D.M. Vigushin, H. Linardou Two weekly vinorelbine administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer Eur J Cancer 36 2000 177 182
35. B. Fazeny, U. Zifko, S. Meryn Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel -- A phase II study Cancer Chemother Pharmacol 39 1996 150 156
36. L. Zelek, S. Barthier, M. Riofrio Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma Cancer 92 2001 2267 2272
37. R.B. Livingston, G.K. Ellis, J.R. Gralow Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel- refractory metastatic breast cancer J Clin Oncol 15 1997 1395 1400
38. C. Jara-Sanchez, M. Martin, J.A. Garcia-Saenz Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer a cooperative study by the GEICAM group Clin Breast Cancer 3 2003 399 404
39. P. Prandoni, E. Bernardi Upper extremity deep vein thrombosis Curr Opin Pulm Med 5 1999 222 226
40. C.E. Nightingale, A. Norman, D. Cunningham A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy Eur J Cancer 33 1997 398 403
41. S. Partridge, M. Leslie, A. Irvine Infusional 5-fluorouracil can be a pain in the neck a case for repositioning displaced Hickman lines Clin Oncol (R Coll Radiol) 11 1999 274 276
42. M. Verso, G. Agnelli Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 2003 3665 3675
43. G. Liu, E. Franssen, M. Fitch Patient preferences for oral versus intravenous palliative chemotherapy J Clin Oncol 15 1997 110 115
44. M.M. Borner, P. Schöffski, R. de Wit Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin a randomised crossover trial in advanced colorectal cancer Eur J Cancer 38 2002 349 358
45. Miles D, O' Shaughnessy JA, Vukelja S. Survival benefit with capecitabine plus docetaxel versus docetaxel: analysis of post-study therapy in a randomized, phase III trial. Clin Breast Cancer (in press).
46. S. Reyes, L. Torrecillas, A. Acosta Capecitabine and taxanes: combination versus sequential therapy in anthracycline-pretreated metastatic breast cancer (MBC): findings from the Mexican Oncology Study Group (MOSG) phase III trial [abstract 447] Eur J Cancer 1 suppl 5 2003 S136